RE:Pharma faces looming patent cliff - seller's market in bioDavid Wainer of the Wall Street Journal (WSJ) recenty wrote that it's a "seller's market in biotech," thanks in part to the "diminishing list of desirable biotechs" and the fact that other pharma companies are in Pfizer's shoes: "About $200 billion in sales is going off patent this decade." In his view, it makes sense that Pfizer is emerging as "one of the most aggressive deal makers," citing those strong COVID earnings but also the patent cliff and waning COVID market.